¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active gradient shielding"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gradient limiting reabsorption
    ³óµµ°æ»çÁ¦ÇÑÀçÈí¼ö
  • gradient magnetic field
    ±â¿ï±âÀÚ±âÀå, °æ»çÀÚ±âÀå
  • gradient method
    °è´Ü°Ë»ç¹ý
  • gradient moment
    ±â¿ï±â¸ð¸àÆ®
  • gradient moment nulling
    ±â¿ï±â¸ð¸àÆ®¹«È¿È­
  • gradient motion rephasing
    ±â¿ï±â¿îµ¿ÀçÀ§»óÈ­
  • gradient refocused acquisition
    ±â¿ï±âÀçÃÊÁ¡È¹µæ
  • gradient refocused imaging
    ±â¿ï±âÀçÃÊÁ¡¿µ»ó
  • gradient slope
    °æ»ç±â¿ï±â
  • ion gradient
    À̿±â¿ï±â, À̿°æ»ç
  • imaging gradient
    ¿µ»ó±â¿ï±â
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • motion compensation gradient
    ¿îµ¿º¸»ó±â¿ï±â
  • maximum gradient strength
    ÃÖ´ë±â¿ï±â¼¼±â, ÃÖ´ë°æ»ç°­µµ
  • magnetic field gradient
    ÀÚÀå±â¿ï±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • flow compensation gradient technique
    È帧º¸»ó±â¿ï±â±â¹ý
  • flow sensitive gradient echo sequence
    È帧¹Î°¨±â¿ï±â¸Þ¾Æ¸®¿¬¼â
  • frequency encoding gradient
    Á֯ļöºÎȣȭ±â¿ï±â
  • gradient magnetic field
    ±â¿ï±âÀÚ±âÀå, °æ»çÀÚ±âÀå
  • gradient
    ±â¿ï±â, °æ»ç
  • gradient method
    °è´ÜÀû°Ë»ç¹ý
  • gradient moment
    ±â¿ï±â¸ð¸àÆ®
  • gradient slope
    °æ»ç±â¿ï±â
  • gradient acquisition imaging
    ±â¿ï±âȹµæ¿µ»ó
  • gradient echo imaging
    ±â¿ï±â¿¡ÄÚ¿µ»ó
  • gradient echo technique
    ±â¿ï±â¿¡ÄÚ¹ý
  • gradient echo pulse sequence
    ±â¿ï±â¸Þ¾Æ¸®ÆÞ½º¿¬¼â
  • gradient limiting reabsorption
    ³óµµÁõ°¨Á¦ÇÑÀçÈí¼ö
  • gradient moment nulling
    ±â¿ï±â¸ð¸àÆ®¹«È¿È­
  • gradient motion rephasing
    ±â¿ï±â¿îµ¿ÀçÀ§»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • active treatment
    Á÷Á¢Ä¡·á, Àû±Ø¿ä¹ý(îÝпèþÛö).
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ(Áõ)(üÀÔÑàõÌ¿ú·ñø).
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • hepatitis,chronic active
    ¸¸¼ºÈ°µ¿¼º(Ø·àõüÀÔÑàõ)
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • positive placebo =active p.
    ¾ç¼ºÇö󼼺¸, Ç¥Áؾà(øöñÞå·).
  • probe electrode =active e.
    Ž»öÀü±Ø.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • density gradient
    ¹Ðµµ(Áõ°¨)À², ¹Ðµµ±¸¹è(ÚËÓøÏ£ÛÕ).
  • density gradient centrifugation
    ¹Ðµµ±¸¹è¿ø½ÉºÐ¸®.
  • diffusion gradient pulse
    È®»ê °æ»ç ÆÞ½º
  • electric potential gradient
    ÀüÀ§(îïêÍ)±â¿ï±â.
  • electrical gradient
    Àü±â±¸¹è(ÎþÛÕ)
  • electrochemical gradient
    Àü±âÈ­ÇÐÀû ±¸¹è(Ï£ÛÕ)(°æ»ç(ÌËÞØ))
  • electrochemical potential gradient
    Àü±âÈ­ÇÐÀüÀ§(ï³Ñ¨ûùùÊï³êÈ)±â¿ï±â.
  • electrochemical potential gradient
    Àü±âÈ­ÇÐÀüÀ§±â¿ï±â.
  • electrochemicaql potential gradient
    Àü±âÈ­ÇÐÀûÀüÀ§±¸¹è(°æ»ç)
  • epidemiological gradient
    ¿ªÇÐÀû ±¸¹è.
  • equilibrium density gradient centrifugation
    ÆòÇü¹Ðµµ±¸¹è¿ø½É¹ý(¡­ÚËöôÎþÛÕêÀãýÛö).
  • fast gradient recalled echo method
    °í¼Ó °æ»ç ȸº¹ ¿¡ÄÚ ±â¹ý
  • fast multiplanar spoiled gradient recalled sequence
    °í¼Ó ´Ù¸é ȸ¼Õ °æ»ç ȸº¹ ¿¬¼â
  • field gradient
    ÀÚÀå °æ»ç
  • flow compensation gradient technique
    À¯µ¿ º¸»ó °æ»ç ±â¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • active mediated transport
    ´Éµ¿¸Å°³¼ö¼Û (ÒöÔÑØÚË¿âÃáê)
  • active methionine
    Ȱ¼º(üÀàõ)¸ÞŸÀÌ¿À´Ñ
  • active methyl
    Ȱ¼º(üÀàõ)¸ÞÆ¿
  • active patch
    Ȱ¼º(üÀàõ)ÆÖÄ¡
  • active phosphate
    Ȱ¼ºÀλ꿰 (üÀàõ ×òß«ç¤)
  • active phospholipid
    Ȱ¼ºÀÎÁöÁú (üÀàõ×òò·òõ)
  • active pyrophosphate
    Ȱ¼º(üÀàõ)ÇÇ·ÎÀλ꿰 (×òß«ç¤)
  • active pyruvate
    Ȱ¼º(üÀàõ)ÆÄÀÌ·çºê»ê¿° (ß«ç¤)
  • active site
    Ȱ¼º(üÀàõ)ÀÚ¸®
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • active sulfate
    Ȱ¼ºÈ²»ê¿° (üÀàõüÜß«ç¤)
  • active translocation
    Ȱ¼ºÀüÀ§ (üÀàõï®êÈ)
  • active transport
    ´Éµ¿¼ö¼Û (ÒöÔÑâÃáê)
  • flexible active site
    °¡º¯(ʦܨ) Ȱ¼º(üÀàõ)ÀÚ¸®
  • primary active transport
    ÀÏÂ÷ ´Éµ¿¼ö¼Û(ìéó­ÒöÔÑâÃáê)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • rephasing gradient motion
    ÀçÀ§»ó°æ»ç¿îµ¿
  • rewinder gradient
    µÇ°¨±â°æ»ç
  • shielded gradient
    Â÷Æó°æ»ç
  • shielded gradient coil
    Â÷Æó°æ»çÄÚÀÏ
  • slice selection gradient
    ÀýÆí¼±Åðæ»ç
  • slice selection gradient field
    ÀýÆí¼±Åðæ»çÀå
  • spoiler gradient
    ÈѼհæ»ç
  • susceptibility gradient
    ÀÚÈ­À²°æ»ç
  • volume gradient echo technique
    ¿ëÀû°æ»ç¿¡ÄÚ±â¹ý
  • X gradient
    XÃà °æ»ç
  • Y gradient
    YÃà °æ»ç
  • Z gradient
    ZÃà°æ»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MDG mean diastolic gradient; methyladenine deoxyribonucleic acid glycosylase
MPGR multiple planar gradient recalled
MP-RAGE magnetization-prepared rapid gradient-echo
NEPHGE nonequilibrated pH gradient electrophoresis
PPG photoplethysmography; platelet proteoglycan; portal pressure gradient
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
GGE gradient gel electrophoresis
MP RAGE magnetization prepared rapid acquisition gradient echo
PG pressure gradient
SGE spoiled gradient echo
SPGR spoiled gradient echo
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 5
chronic active hepatitis <pathology> This is a form of continuing liver inflammation that results in liver cell death. Causes include viral infection (hepatitis D, hepatitis B, hepatitis C), autoimmune disease, drug ingestion or metabolic causes. Chronic active hepatitis will lead to hepatic failure and death in a small percentage of these patients.
(27 Sep 1997)
chronic active inflammation The coexistence of chronic inflammation and superimposed acute inflammation.
(05 Mar 2000)
chronic active liver disease Any of several types of hepatitis persisting for more than six months, often progressing to cirrhosis.
Synonym: chronic active liver disease.
(05 Mar 2000)
specific active immunity See: acquired immunity.
(05 Mar 2000)
surface-active Indicating the property of certain agents of altering the physicochemical nature of surfaces and interfaces, bringing about lowering of interfacial tension; they usually possess both lipophilic and hydrophilic groups.
See: surfactant.
(05 Mar 2000)
surface-active agent Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics.
(12 Dec 1998)
surface active compound <biochemistry> Usually, in biological systems, means a detergent like molecule that is amphipathic and that will bind to the plasma membrane or to a surface with which cells come in contact, altering its properties from hydrophobic to hydrophilic or vice versa.
(18 Nov 1997)
immunity, active Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination.
(12 Dec 1998)
immunotherapy, active Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as bcg vaccine and corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
(12 Dec 1998)
optically active <chemistry> A material which can rotate plane-polarized light.
(09 Jan 1998)
tensio active Having an effect on surface tension.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á